Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

MLA

Rugo, Hope S., et al. “Safety Analyses from the Phase 3 ASCENT Trial of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.” NPJ Breast Cancer, vol. 8, no. 1, Aug. 2022, p. 98. EBSCOhost, https://doi.org/10.1038/s41523-022-00467-1.

APA

Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Diéras, V., Carey, L. A., Gianni, L., Piccart, M. J., Loibl, S., Goldenberg, D. M., Hong, Q., Olivo, M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer, 8(1), 98. https://doi.org/10.1038/s41523-022-00467-1

Chicago

Rugo, Hope S, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A Hurvitz, Joyce O’Shaughnessy, et al. 2022. “Safety Analyses from the Phase 3 ASCENT Trial of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.” NPJ Breast Cancer 8 (1): 98. doi:10.1038/s41523-022-00467-1.